Roth Capital Reiterates Buy on Bioage Labs, Maintains $25 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.0%

Neg 0% Neu 90% Pos 0%

Roth Capital analyst Adam Walsh reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $25 price target.

Comments

No comments yet. Be the first!